Targeted Oncology

ASCENT-04: Outcomes With Sacituzumab Govitecan Plus Pembrolizumab In First-Line TNBC

Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of ...
Monthly Prescribing Reference

Sacituzumab Govitecan Meets Endpoint in First-Line mTNBC Trial

Sacituzumab govitecan-hziy significantly improved progression free survival over standard chemotherapy in untreated mTNBC patients ineligible for immunotherapy. Topline data were announced from a ...
Business Wire

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to ...
Monthly Prescribing Reference

Sacituzumab Govitecan Gets Priority Review for HR+/HER2- Metastatic Breast Cancer

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase ...